Phase 2 trial initiated for depression treatment targeting specific biomarker
EmbarkNeuro, a neuroscience biotech company formerly known as Ancora Bio, announced its phase 2 trial is under way for ANC-501, a first-in-class vasopressin 1b receptor antagonist for the treatment of major depressive disorder. The trial, an 8-week single-arm study, will assess the efficacy of ANC-501 when added to a standard antidepressant therapy in patients with biomarker-confirmed disruption
Source: healio.com